Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 1/20 | 0.73 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.73 |
| ▸ | RNF4 | P78317 | 1/20 | 0.71 |
| ▸ | HPGD | P15428 | 4/20 | 0.67 |
| ▸ | RAB9A | P51151 | 3/20 | 0.67 |
| ▸ | NPC1 | O15118 | 2/20 | 0.67 |
| ▸ | MAPT | P10636 | 2/20 | 0.67 |
| ▸ | CRHBP | P24387 | 1/20 | 0.67 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.67 |
| ▸ | GAA | P10253 | 1/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.63 |
| ▸ | RECQL | P46063 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12391324 | 0.89 | MTNR1A (0.60) | MTNR1AMTNR1BRNF4HPGDRAB9A | |
| SCHEMBL12391323 | 0.89 | MTNR1A (0.60) | MTNR1AMTNR1BRNF4HPGDRAB9A | |
| SCHEMBL2000889 | 0.87 | RNF4 (0.77) | RNF4HPGDRAB9ANPC1MAPT | |
| SCHEMBL2172248 | 0.86 | MTNR1A (0.64) | MTNR1AMTNR1BHPGDRAB9ANPC1 | |
| SCHEMBL14447211 | 0.86 | MTNR1A (0.64) | MTNR1AMTNR1BHPGDRAB9ANPC1 | |
| SCHEMBL2169725 | 0.86 | MTNR1A (0.78) | MTNR1AMTNR1BHPGDRAB9ANPC1 | |
| SCHEMBL2170997 | 0.85 | MTNR1A (0.62) | MTNR1AMTNR1BHPGDMAPTGAA | |
| SCHEMBL2171671 | 0.85 | L3MBTL1 (0.68) | MTNR1AMTNR1BRNF4HPGDMAPT | |
| SCHEMBL8142314 | 0.85 | MTNR1B (1.00) | MTNR1AMTNR1BHPGDSMN1; SMN2KMT2A | |
| SCHEMBL28759929 | 0.84 | PNLIP (0.64) | MTNR1AMTNR1BRNF4HPGDRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230127728-A1 | MODIFIED GRAPHENE, METHOD OF PRODUCING MODIFIED GRAPHENE, MODIFIED GRAPHENE-RESIN COMPOSITE, MODIFIED GRAPHENE SHEET, AND MODIFIED GRAPHENE DISPERSION | CANON KK (JP) | 2023-04-27 | — | — | US | disclosed |
| US-11518889-B2 | Modified graphene, method of producing modified graphene, modified graphene-resin composite, modified graphene sheet, and modified graphene dispersion | CANON KABUSHIKI KAISHA (JP) | 2022-12-06 | — | — | US | disclosed |
| US-20200270463-A1 | MODIFIED GRAPHENE, METHOD OF PRODUCING MODIFIED GRAPHENE, MODIFIED GRAPHENE-RESIN COMPOSITE, MODIFIED GRAPHENE SHEET, AND MODIFIED GRAPHENE DISPERSION | CANON KABUSHIKI KAISHA (JP) | 2020-08-27 | — | — | US | disclosed |
| WO-2019079759-A1 | BROAD SPECTRUM ANTIVIRULENCE, ANTI-PERSISTENCE COMPOUNDS | RAHME LAURENCE (US) | 2019-04-25 | — | — | WO | disclosed |
| EP-2349252-A2 | SYNERGISTIC COMBINATION OF SPHINGOSINE-1-PHOSPHATE RECEPTOR ANTAGONISTS AND ANTIMICROTUBULE AGENTS | Exelixis, Inc. (US) | 2011-08-03 | — | — | EP | disclosed |
| EP-2346821-A1 | SPHINGOSINE-1-PHOSPHATE RECEPTOR ANTAGONISTS | Exelixis, Inc. (US) | 2011-07-27 | — | — | EP | disclosed |
| WO-2010045580-A1 | SPHINGOSINE-1-PHOSPHATE RECEPTOR ANTAGONISTS | EXELIXIS, INC. (US) | 2010-04-22 | — | — | WO | disclosed |
| WO-2010045601-A2 | SYNERGISTIC EFFECTS BETWEEN SPHINGOSINE-1-PHOSPHATE RECEPTOR ANTAGONISTS AND ANTIMICROTUBULE AGENTS | EXELIXIS, INC. (US) | 2010-04-22 | — | — | WO | disclosed |
| US-20080207718-A1 | Use of Fused Imidazole Derivatives to Mediate Ccr3 Related Conditions | BECKWITH ROHAN | 2008-08-28 | — | — | US | disclosed |
| US-20080207718-A1 | Use of Fused Imidazole Derivatives to Mediate Ccr3 Related Conditions | BECKWITH ROHAN | 2008-08-28 | — | — | US | disclosed |
| WO-2007025751-A1 | USE OF FUSED IMIDAZOLE DERIVATIVES TO MEDIATE CCR3 RELATED CONDITIONS | NOVARTIS AG (CH) | 2007-03-08 | — | — | WO | disclosed |
| CN-1314906-A | Salts of paroxetine | SMITHKLINE BEECHAM PLC (GB) | 2001-09-26 | — | — | CN | disclosed |
| EP-0677039-B1 | CYCLOBUTANE DERIVATIVES AS INHIBITORS OF SQUALENE SYNTHETASE AND PROTEIN FARNESYLTRANSFERASE | ABBOTT LAB (US) | 1999-03-10 | — | — | EP | disclosed |
| US-5783593-A | FUNGICIDE; ANTICHOLESTEROL AGENT | ABBOTT LABORATORIES (US) | 1998-07-21 | — | — | US | disclosed |
| US-5631401-A | Inhibitors of protein farnesyltransferase and squalene synthase | ABBOTT LABORATORIES (US) | 1997-05-20 | — | — | US | disclosed |
| WO-1996034850-A1 | CYCLOBUTANE DERIVATIVES AND THEIR USE AS INHIBITORS OF PROTEIN FARNESYLTRANSFERASE | ABBOTT LABORATORIES (US) | 1996-11-07 | — | — | WO | disclosed |
| EP-0677039-A1 | CYCLOBUTANE DERIVATIVES AS INHIBITORS OF SQUALENE SYNTHETASE AND PROTEIN FARNESYLTRANSFERASE | Abbott Laboratories (US) | 1995-10-18 | — | — | EP | disclosed |
| WO-1995021815-A1 | CYCLOBUTANE DERIVATIVES AND THEIR USE AS INHIBITORS OF PROTEIN FARNESYLTRANSFERASE AND SQUALENE SYNTHASE | ABBOTT LABORATORIES (US) | 1995-08-17 | — | — | WO | disclosed |
| WO-1995012572-A1 | CYCLOBUTANE DERIVATIVES AS INHIBITORS OF SQUALENE SYNTHETASE AND PROTEIN FARNESYLTRANSFERASE | ABBOTT LABORATORIES (US) | 1995-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200270463-A1 | MODIFIED GRAPHENE, METHOD OF PRODUCING MODIFIED GRAPHENE, MODIFIED GRAPHENE-RESIN COMPOSITE, MODIFIED GRAPHENE SHEET, AND MODIFIED GRAPHENE DISPERSION | GRIA1, GRIN1, NR3C1 | MTNR1A 215/4885MTNR1B 817/4885RNF4 1532/4885 |
| US-20230127728-A1 | MODIFIED GRAPHENE, METHOD OF PRODUCING MODIFIED GRAPHENE, MODIFIED GRAPHENE-RESIN COMPOSITE, MODIFIED GRAPHENE SHEET, AND MODIFIED GRAPHENE DISPERSION | GRIA1, GRIN1, NR3C1 | MTNR1A 215/4885MTNR1B 806/4885RNF4 1584/4885 |
| US-20080207718-A1 | Use of Fused Imidazole Derivatives to Mediate Ccr3 Related Conditions | CCR3, CCR1, CCR4 | MTNR1A 592/4885MTNR1B 564/4885RNF4 2848/4885 |
| US-11518889-B2 | Modified graphene, method of producing modified graphene, modified graphene-resin composite, modified graphene sheet, and modified graphene dispersion | GRIA1, GRIN1, NR3C1 | MTNR1A 215/4885MTNR1B 817/4885RNF4 1532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.